Physician-backed insights to optimize your health and reduce long-term risks.
An exercise prescription is worth asking for, especially if you have heart disease or are starting from very little activity. The useful version names what to do, how much, how hard, and when someone will check how it's going. A new statement from the American College of Cardiology gives that request clinical backing. Exercise itself has strong evidence behind it, and you don't need to hit 10,000 steps before it starts to count.
If you enjoy unsweetened tea, there's good reason to keep it in your day. A new study of nearly half a million Chinese adults found regular drinkers developed heart and blood-vessel disease less often. The evidence doesn't yet support drinking more than you'd naturally choose. The study's more consistent associations for black tea than green, and its lowest-risk point at several cups a day, come from observation and haven't been tested as a recipe. Staying active and not smoking remain the habits with the stronger evidence behind them.
Brown fat now looks like a credible treatment target: a Nature study of more than 100,000 patients found that people with more active brown fat had markedly less diabetes and heart disease. Whether deliberately switching it on prevents those diseases remains unproven in people, and the blood pressure drug the researchers flagged increased brown-fat activity in cells and mice. You don't have to wait for that answer. In a randomized trial, exercise cut visceral fat without measurably increasing brown-fat activity.
For almost every blood test your doctor orders, you can eat breakfast first. A new analysis of 9.7 million outpatient results in JAMA Internal Medicine found that only a handful of common lab values shift enough with fasting to change your care. The list is short and predictable: glucose, triglycerides, lipase, GGT, and a few others. Long water-only fasts also have real costs, especially if you take insulin or a sulfonylurea.
Ischemic strokes in adults under 55 are rising because the vascular damage of middle age is arriving earlier. High blood pressure, extra weight, elevated blood sugar, and smoking now show up in people's 30s and 40s. The useful part is that the same levers likely work harder in a younger body. Addressing them together is linked to roughly 70% to 80% lower stroke risk, and the benefit is likely largest when you start in your 30s or 40s.
Camzyos (mavacamten), a daily pill, eased the blocked outflow from the heart in teenagers with symptomatic obstructive hypertrophic cardiomyopathy (HCM), much as it does in adults. In the trial that got it approved, no adolescent's pumping function fell below the safety threshold. If the next conversation at your teen's HCM clinic has been about septal myectomy or alcohol ablation, the pill is now an FDA-approved alternative to raise. The approval rests on one small trial that lasted 28 weeks, so how teens do on the drug over years is still unknown.
The FDA has approved Autus, a synthetic pulmonary heart valve that can spare children some of the repeat open-heart surgeries a fixed valve requires. It's sewn in once during open-heart surgery, and as the child grows, a cardiologist can thread a balloon catheter up to it and widen it without opening the chest. It tops out around an adult valve size, so it carries a child through the growing years, and how well it holds up over many years is still being tracked.
If your chlorthalidone bottle shows lot RISA24001, RISB24002, or RISA24002 with an April 2027 expiration, it is on the FDA recall list and should be swapped this week. Any other bottle is fine. The problem is that the tablets may not fully dissolve, so they can act weaker than the label says. Don't stop taking the pill while you sort this out, because interrupting blood pressure therapy is linked to a measured increase in stroke and heart attack risk.
Yes, the recalled Impella is still in use, and if a loved one is on one right now, the pump itself isn't coming out. The FDA's Class I recall targets the wheeled console at the bedside, not the pump threaded into the heart. The console is being fixed through a manufacturer service update. What matters at the bedside is simple: whether the team has a backup controller ready and a written protocol for the alarm that triggered this recall.
A mini-stroke isn't brain damage that dooms you to dementia. It's the vascular system's earliest useful warning about it. A large new study found dementia about a third more common in the years after a transient ischemic attack (TIA), with the sharpest rise in the first year. The studies that looked deepest suggest the fleeting event isn't doing new damage; it's flagging vascular injury already underway. That year is the clearest chance most people get to bend their own dementia trajectory, and it's the year TIA patients are least likely to be treated for it.
A transthoracic echocardiogram bounces high-frequency sound off your heart from outside the chest and turns the echoes into moving pictures, while Doppler reads the speed and direction of blood through the valves. No radiation. Nothing goes inside you, and there's usually no prep. That makes it the natural first look when a symptom, a murmur, or suspected heart failure raises a specific question. A clearly abnormal study is often enough to guide the next move. A clean one is sometimes only the first step.
Your Apple Watch can tell you something real about aging-related health, just not as a single age. The measures Apple feeds into its new Health Age score are among the better-studied things you can track on your own: fitness, resting heart rate, sleep, HRV, and optional labs. Several are tied to future health outcomes, and several can be improved. The score built on top of them is another matter. As of September 10, 2026, no peer-reviewed study was found showing Apple's Health Age predicts disease or death, so watch the ingredients, not the verdict.
A cloth tape around your middle tells you something a scale can't: whether you're carrying the deep belly fat that drives heart disease and diabetes risk. For most adults, the target is a waist under half your height. That rule is now backed by a 2026 JAMA Network Open analysis and the UK's 2025 NICE guideline, and the tape is the cheapest useful home health number after a blood pressure cuff.
If your systolic runs 140 or higher, getting it under 130 now has randomized evidence for your brain, not only your heart. Intensive blood pressure control lowered new dementia cases by about 15% over seven years, and did it with fewer serious adverse events in the treated group than in usual care. That closes a gap the field has been carrying since SPRINT MIND.
Yes. On August 28, 2026, the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It joins semaglutide, liraglutide, and dulaglutide as a heart-protection option in this group. What tipped the approval wasn't a lower heart-attack rate. It was fewer deaths.
If you're 70 or older, a statin is worth considering when your chance of a first major cardiovascular event is high enough to make daily medication worth it. The new STAREE atorvastatin trial strengthens that case, but it doesn't turn age itself into a reason to start. It found fewer events in a broad endpoint that included cardiovascular death, nonfatal heart attack, stroke, and coronary revascularization. The reduction was driven mainly by fewer heart attacks and coronary procedures. It did not extend disability-free survival. So the useful question is personal: how much event risk are you trying to prevent?
Lipfendra (enlicitide) is the first once-daily oral PCSK9 inhibitor, a pill that lowered LDL cholesterol by about 56 percent beyond a placebo pill in a roughly 2,900-person trial. Its reported list price is about $315 a month, but it has not yet been shown to prevent heart attacks or strokes.
Four changes lower blood pressure with the clearest evidence, no new device or supplement required: a DASH-style eating pattern, cutting sodium, regular exercise, and losing weight if you carry extra. Most start working within weeks. Across trials and meta-analyses they tend to drop the top number by about 3 to 12 points, more if you start higher. What lifestyle can't do is replace urgent care or medication when your risk or your reading demands it.
ApoB is a single blood test that counts artery-clogging particles a normal LDL cholesterol result can miss. For most people, the two numbers rise and fall together, so LDL-C still works reasonably well. But in some people, especially those with high triglycerides, diabetes, extra weight, metabolic syndrome, or very low LDL-C on treatment, ApoB can run high while LDL-C looks reassuring. In those discordant cases, heart attack and atherosclerosis-related risk often follows ApoB more closely. That makes ApoB worth checking if your LDL-C looks fine but your risk picture does not.
A high HDL on your lipid panel is most reassuring when it's modestly high and the rest of your numbers are favorable: low LDL, low non-HDL cholesterol or apoB, low triglycerides, normal blood pressure and glucose. The label "good cholesterol" stops holding at the top of the range. Across large cohorts, risk is often lowest in a middle zone, roughly the 50s through 70s, while very high numbers, around 80 to 90 and above, are linked in several studies to more cardiovascular events or mortality, not less. The useful question isn't how to push HDL higher, but whether the rest of your lipid and metabolic picture is actually favorable.
